The French Gut-colo
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-75
SponsorInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
About this trial
Colorectal cancer (CRC) is the second most common type of cancer worldwide. The European Union recommends national CRC screening for people aged between 50 and 74. Generally, an immunological test called FIT (Fecal Immunochemical Test), based on the quantitative detection of human haemoglobin, is performed on a stool sample. If the haemoglobin level is above the recommended threshold, a colonoscopy is recommended to detect colorectal lesions. Recent studies have identified potential microbiota signatures associated with colon cancer. In this study, we will analyze the microbiota of a population aged 50 to 75 years undergoing colonoscopy as part of routine care in order to confirm the presence of microbiota signatures associated with the presence of adenomas, advanced adenomas and CRC.
Eligibility criteria
Qualifiers
Between the ages of 50 and 75
Requiring colonoscopy
Able to provide a faecal sample and to perform a FIT test prior to colonoscopy
Without known inflammatory bowel disease (chronic inflammatory bowel disease (IBD), chronic ulcerative colitis (CUC) and Crohn's disease (CD))
Disqualifiers
Persons not living in France (declaratory);
Persons subject to a protective measure, in particular guardianship or trusteeship, or unable to express their consent (declarative);
Persons who have had a colectomy (declaratory);
Person with a digestive stoma (declaration);
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborator
Source ClinicalTrials.gov